Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: treprostinil sodium Clear all

Conditions: Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: Inhaled treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peripheral Vascular Disease
Interventions: Remodulin (treprostinil sodium) Injection; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 4
States / cities: Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: IV Remodulin, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 1 Hour to 14 Days
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions: Remodulin® (treprostinil sodium) Injection; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium 314d Modified Release Tablets, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Treprostinil sodium for inhalation; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more

Conditions: Pulmonary Hypertension
Interventions: Inhaled treprostinil, Placebo inhalation solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Jacksonville, Florida • Weston, Florida

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Treprostinil Inhalation Solution, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: treprostinil, Crono Five ambulatory pump; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Oklahoma City, Oklahoma

Search by objective public record fields.

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Beraprost-314d Added-on to Tyvaso® (BEAT)

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH